Sofinnova Investments’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Sofinnova Investments’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-159,512	Closed	-$3.51M	–	74
2019 Q4	$3.51M	Sell	159,512 -183,243	-53%	-$3.69M	0.25%	51
2019 Q3	$4.92M	Buy	+342,755	New	+$4.9M	0.45%	43

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Sofinnova Investments's DRNA Position: Q1 2020 in Review

Sofinnova Investments sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 159,512 shares — an estimated $3.51M sold.

Sofinnova Investments first reported a position in DRNA in Q3 2019 and held it in 2 quarters. The position peaked at $4.92M in Q3 2019. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

Sofinnova Investments reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Sofinnova Investments sold 159,512 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $3.51M.
Sofinnova Investments first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and held it in 2 quarters.
Sofinnova Investments's Dicerna Pharmaceuticals, Inc. position peaked at $4.92M in Q3 2019.
144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.